Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis
© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ..
Fibrillar glomerulonephritis (FGN) is a rare proliferative form of glomerular disease characterised by randomly oriented fibrillar deposits with a mean diameter of 20 nm. It has a rare association with systemic lupus erythematosus (SLE). We report the case of a female in her mid-50's with a 20 year history of SLE, who developed proteinuria due to FGN and had no histological evidence of lupus nephritis. She was maintained on azathioprine and prednisolone. A renal biopsy revealed randomly arranged fibrillar deposits that positively stained for DNAJB9, consistent with a diagnosis of FGN. Azathioprine was switched to mycophenolate mofetil, and the patient showed significant improvement in proteinuria. This case-based review describes the diagnosis, management and clinical outcome of FGN in association with SLE in the absence of lupus nephritis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
BMJ case reports - 16(2023), 2 vom: 21. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Whelband, Matthew Carl [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 24.02.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bcr-2022-253388 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353166421 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353166421 | ||
| 003 | DE-627 | ||
| 005 | 20231226055402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bcr-2022-253388 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353166421 | ||
| 035 | |a (NLM)36810336 | ||
| 035 | |a (PII)e253388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Whelband, Matthew Carl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a Fibrillar glomerulonephritis (FGN) is a rare proliferative form of glomerular disease characterised by randomly oriented fibrillar deposits with a mean diameter of 20 nm. It has a rare association with systemic lupus erythematosus (SLE). We report the case of a female in her mid-50's with a 20 year history of SLE, who developed proteinuria due to FGN and had no histological evidence of lupus nephritis. She was maintained on azathioprine and prednisolone. A renal biopsy revealed randomly arranged fibrillar deposits that positively stained for DNAJB9, consistent with a diagnosis of FGN. Azathioprine was switched to mycophenolate mofetil, and the patient showed significant improvement in proteinuria. This case-based review describes the diagnosis, management and clinical outcome of FGN in association with SLE in the absence of lupus nephritis | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological agents | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Renal medicine | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 7 | |a Azathioprine |2 NLM | |
| 650 | 7 | |a MRK240IY2L |2 NLM | |
| 650 | 7 | |a DNAJB9 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Molecular Chaperones |2 NLM | |
| 650 | 7 | |a HSP40 Heat-Shock Proteins |2 NLM | |
| 700 | 1 | |a Willingham, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Thirunavukkarasu, Sathiamalar |e verfasserin |4 aut | |
| 700 | 1 | |a Patrick, Jean |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ case reports |d 2008 |g 16(2023), 2 vom: 21. Feb. |w (DE-627)NLM209291001 |x 1757-790X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:2 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bcr-2022-253388 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 2 |b 21 |c 02 | ||